Mesoblast Quote - MESO

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

15.85

Bid

15.75

Ask

16.00

Volume

3,986,376

14.35 Day's Range 19.1489

0.00 52 Week Range 0.00

Market Cap

1.81B

Previous Close

12.25

Open

18.65

Last Trade

15.99

Last Trade Time

18:33:08

Financial Volume

US$ 65,999,968

VWAP

16.5564

Average Volume (3m)

Shares Outstanding

114,178,411

Dividend Yield

PE Ratio

-3.25

Earnings Per Share (EPS)

-0.77

Revenue

9.25M

Net Profit

-87.96M

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-... Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.mesoblast.com

Headquarters

Melbourne, Victoria, Aus

Founded

Mesoblast Limited is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MESO. The last closing price for Mesoblast was US$12.25. Over the last year, Mesoblast shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Mesoblast currently has 114,178,411 shares outstanding. The market capitalization of Mesoblast is US$1.40 billion. Mesoblast has a price to earnings ratio (PE ratio) of -3.25.

Overall Flow

Bullish

Net Premium

1M

Calls / Puts

314.29%

Buys / Sells

91.67%

OTM / ITM

11.54%

Sweeps Ratio

0.00%

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and...

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming...

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

MESO - Frequently Asked Questions (FAQ)

What is the current Mesoblast share price?

The current share price of Mesoblast is US$ 15.85

How many Mesoblast shares are in issue?

Mesoblast has 114,178,411 shares in issue

What is the market cap of Mesoblast?

The market capitalisation of Mesoblast is USD 1.4B

What is the 1 year trading range for Mesoblast share price?

Mesoblast has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Mesoblast?

The price to earnings ratio of Mesoblast is -3.25

What is the cash to sales ratio of Mesoblast?

The cash to sales ratio of Mesoblast is 30.86

What is the reporting currency for Mesoblast?

Mesoblast reports financial results in USD

What is the latest annual turnover for Mesoblast?

The latest annual turnover of Mesoblast is USD 9.25M

What is the latest annual profit for Mesoblast?

The latest annual profit of Mesoblast is USD -87.96M

What is the registered address of Mesoblast?

The registered address for Mesoblast is LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, 3000

What is the Mesoblast website address?

The website address for Mesoblast is www.mesoblast.com

Which industry sector does Mesoblast operate in?

Mesoblast operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
APTOAptose Biosciences Inc	US$ 0.373 (119.15%)	47.85M
NVNINVNI Group Ltd	US$ 5.68 (112.73%)	11M
AADIAadi Bioscience Inc	US$ 3.84 (65.52%)	1.15M
XLOXilio Therapeutics Inc	US$ 1.33 (41.79%)	4.46M
AMODAlpha Modus Holdings Inc	US$ 4.49 (28.65%)	9.15k
MTEMMolecular Templates Inc	US$ 0.1903 (-45.63%)	3M
XHGXChange TED Inc	US$ 0.96 (-26.15%)	223.32k
PRFXPainReform Ltd	US$ 8.28 (-25.81%)	1.21M
MOBXMobix Labs Inc	US$ 1.56 (-25.18%)	257.65k
AVGRAvinger Inc	US$ 0.5799 (-19.02%)	909.02k
APTOAptose Biosciences Inc	US$ 0.373 (119.15%)	47.85M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.5899 (3.49%)	24.04M
NVNINVNI Group Ltd	US$ 5.68 (112.73%)	11M
RGTIRigetti Computing Inc	US$ 6.80 (-8.97%)	5.3M
NVDANVIDIA Corporation	US$ 130.7099 (0.02%)	4.76M